Biocept, Inc. (BIOC): Price and Financial Metrics


Biocept, Inc. (BIOC): $3.17

-0.13 (-3.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BIOC POWR Grades


  • Value is the dimension where BIOC ranks best; there it ranks ahead of 91.91% of US stocks.
  • BIOC's strongest trending metric is Growth; it's been moving down over the last 157 days.
  • BIOC ranks lowest in Stability; there it ranks in the 3rd percentile.

BIOC Stock Summary

  • Price to trailing twelve month operating cash flow for BIOC is currently 54.28, higher than 91.88% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of 388.76%, Biocept Inc's debt growth rate surpasses 96.99% of about US stocks.
  • Revenue growth over the past 12 months for Biocept Inc comes in at 512.86%, a number that bests 98.33% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Biocept Inc are ITCI, SRAX, APDN, NBRV, and AVEO.
  • Visit BIOC's SEC page to see the company's official filings. To visit the company's web site, go to biocept.com.

BIOC Valuation Summary

  • BIOC's EV/EBIT ratio is -24.3; this is 182.94% lower than that of the median Healthcare stock.
  • Over the past 92 months, BIOC's price/sales ratio has gone down 304.2.
  • BIOC's price/sales ratio has moved down 304.2 over the prior 92 months.

Below are key valuation metrics over time for BIOC.

Stock Date P/S P/B P/E EV/EBIT
BIOC 2021-08-31 1.0 1.8 -24.2 -24.3
BIOC 2021-08-30 0.9 1.8 -23.6 -23.7
BIOC 2021-08-27 0.9 1.8 -23.5 -23.5
BIOC 2021-08-26 0.9 1.7 -23.2 -23.2
BIOC 2021-08-25 0.9 1.8 -23.5 -23.5
BIOC 2021-08-24 0.9 1.7 -22.6 -22.5

BIOC Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -53.06%.
  • Its year over year net cashflow from operations growth rate is now at 40.8%.
  • The 5 year price growth rate now stands at -99.39%.
BIOC's revenue has moved up $60,107,072 over the prior 15 months.

The table below shows BIOC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 65.7841 1.023974 3.100931
2021-06-30 54.90074 -5.005328 -2.20445
2021-03-31 43.77104 -13.66441 -6.866274
2020-12-31 27.4614 -19.7871 -17.80968
2020-09-30 10.73391 -24.15599 -25.44706
2020-06-30 5.677024 -23.04972 -26.26049

BIOC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BIOC has a Quality Grade of D, ranking ahead of 15.64% of graded US stocks.
  • BIOC's asset turnover comes in at 1.212 -- ranking 14th of 81 Healthcare stocks.
  • SSY, LH, and MGLN are the stocks whose asset turnover ratios are most correlated with BIOC.

The table below shows BIOC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.212 0.411 -0.069
2021-03-31 1.070 0.374 -0.312
2020-12-31 0.768 0.223 -1.341
2020-09-30 0.379 -0.323 -4.029
2020-06-30 0.239 -0.968 -4.770
2020-03-31 0.290 -0.903 -5.429

BIOC Price Target

For more insight on analysts targets of BIOC, see our BIOC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.00 Average Broker Recommendation 1.5 (Moderate Buy)

BIOC Stock Price Chart Interactive Chart >

Price chart for BIOC

BIOC Price/Volume Stats

Current price $3.17 52-week high $8.38
Prev. close $3.30 52-week low $3.13
Day low $3.13 Volume 179,775
Day high $3.34 Avg. volume 218,318
50-day MA $3.76 Dividend yield N/A
200-day MA $4.04 Market Cap 53.39M

BIOC Latest News Stream


Event/Time News Detail
Loading, please wait...

BIOC Latest Social Stream


Loading social stream, please wait...

View Full BIOC Social Stream

Latest BIOC News From Around the Web

Below are the latest news stories about Biocept Inc that investors may wish to consider to help them evaluate BIOC as an investment opportunity.

Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?

Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year.

Yahoo | January 7, 2022

Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10

SAN DIEGO, January 04, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the Biocept presentation can be accessed on the Investor Relations section of the company website beginning on January 10, 2022 at 7:00 a.m. Eastern time.

Yahoo | January 4, 2022

Biocept (NASDAQ:BIOC) Raised to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a research note issued to investors on Monday morning, Zacks.com reports. The brokerage currently has $4.25 price objective on the medical research companys stock. According to Zacks, Biocept, Inc. is a commercial stage oncology diagnostics company. It has []

Transcript Daily | December 24, 2021

Biocept (NASDAQ:BIOC) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a report released on Monday, Zacks.com reports. Zacks Investment Research currently has $4.25 price target on the medical research company’s stock. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms […] The post Biocept (NASDAQ:BIOC) Upgraded at Zacks Investment Research appeared first on ETF Daily News .

ETF Daily News | December 23, 2021

Biocept (NASDAQ:BIOC) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a report issued on Friday morning, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing […]

Dakota Financial News | December 13, 2021

Read More 'BIOC' Stories Here

BIOC Price Returns

1-mo -17.02%
3-mo -18.93%
6-mo -23.80%
1-year N/A
3-year -86.16%
5-year -99.36%
YTD -12.43%
2021 -18.47%
2020 55.24%
2019 -66.74%
2018 -95.85%
2017 -10.39%

Continue Researching BIOC

Want to see what other sources are saying about Biocept Inc's financials and stock price? Try the links below:

Biocept Inc (BIOC) Stock Price | Nasdaq
Biocept Inc (BIOC) Stock Quote, History and News - Yahoo Finance
Biocept Inc (BIOC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8831 seconds.